Cellular prostatic acid phosphatase (cPAcP) serves as a useful biomarker of histone deacetylase (HDAC) inhibitors in prostate cancer cell growth suppressio
Histone deacetylase inhibitors (HDACi) represent a promising class of epigenetic agents with antican...
Prostatic carcinoma is a significant cause of male cancer death. The majority of cases present as in...
Supplementary Figure 10. Histone deacetylase activity is enriched in NEPC and inhibited by romidepsi...
BACKGROUND: Prostate cancer (PCa) is the most commonly diagnosed solid tumor and the second leading ...
BACKGROUND: Prostate cancer (PCa) is the most commonly diagnosed solid tumor and the second leading ...
We identified the molecular target by histone deacetylase (HDAC) inhibitors for exploring their pote...
Human prostatic acid phosphatase (PAcP) is a 100 kDa glycoprotein composed of two subunits. Recent a...
Purpose: Cytosolic phospholipase A2-α (cPLA -α) provides intracellular arachidonic acid to supply bo...
Purpose: Cytosolic phospholipase A2-α (cPLA 2-α) provides intracellular arachidonic acid to supply b...
Histone deacetylase inhibitors (HDACIs) are showing promise as therapeutic agents for hematological ...
Human prostatic acid phosphatase (PAcP) is a 100 kDa glycoprotein composed of two subunits. Recent a...
Cell cycle re-entry of quiescent cancer cells has been proposed to be involved in cancer progression...
Prostate cancer is the second frequent cause of cancer among men. Prostate Specific Antigen ( PSA) i...
Historically, androgen-deprivation therapy has been the cornerstone for treatment of metastatic pros...
Earlier we identified PPP2CA, which encodes for the a-isoform of protein phosphatase 2A (PP2A) catal...
Histone deacetylase inhibitors (HDACi) represent a promising class of epigenetic agents with antican...
Prostatic carcinoma is a significant cause of male cancer death. The majority of cases present as in...
Supplementary Figure 10. Histone deacetylase activity is enriched in NEPC and inhibited by romidepsi...
BACKGROUND: Prostate cancer (PCa) is the most commonly diagnosed solid tumor and the second leading ...
BACKGROUND: Prostate cancer (PCa) is the most commonly diagnosed solid tumor and the second leading ...
We identified the molecular target by histone deacetylase (HDAC) inhibitors for exploring their pote...
Human prostatic acid phosphatase (PAcP) is a 100 kDa glycoprotein composed of two subunits. Recent a...
Purpose: Cytosolic phospholipase A2-α (cPLA -α) provides intracellular arachidonic acid to supply bo...
Purpose: Cytosolic phospholipase A2-α (cPLA 2-α) provides intracellular arachidonic acid to supply b...
Histone deacetylase inhibitors (HDACIs) are showing promise as therapeutic agents for hematological ...
Human prostatic acid phosphatase (PAcP) is a 100 kDa glycoprotein composed of two subunits. Recent a...
Cell cycle re-entry of quiescent cancer cells has been proposed to be involved in cancer progression...
Prostate cancer is the second frequent cause of cancer among men. Prostate Specific Antigen ( PSA) i...
Historically, androgen-deprivation therapy has been the cornerstone for treatment of metastatic pros...
Earlier we identified PPP2CA, which encodes for the a-isoform of protein phosphatase 2A (PP2A) catal...
Histone deacetylase inhibitors (HDACi) represent a promising class of epigenetic agents with antican...
Prostatic carcinoma is a significant cause of male cancer death. The majority of cases present as in...
Supplementary Figure 10. Histone deacetylase activity is enriched in NEPC and inhibited by romidepsi...